We are grateful to our colleagues for their interest and thoughtful comments on our Seminar about systemic lupus erythematosus (SLE).1 We appreciate the remarks from Qihe Xu, and Thomas Pabst and ...

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025Scott Wolchko To Retire as President and CEO after 10 years of Leadership in ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

Francis S. Kim, MD, has made significant contributions to biomedical research and clinical care for adult and pediatric ...

The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

Systemic Lupus Erythematosus (SLE), commonly known as lupus ... Lupus can affect various parts of the body including the joints, skin, kidneys, liver, blood cells, brain, and gastrointestinal tract.

Nonetheless, in a few specific situations these agents may be considered more strongly: when there is evidence for antibody-mediated destruction of red blood cells and/or platelets intravenous ...

Magnolia Project, an Imperial Beach food pantry, selected more than two dozen struggling South County families to receive a ...

Blood dendritic cell antigen 2 (BDCA2) is expressed in plasmacytoid dendritic cells. These cells’ overproduction of type I interferon is closely linked to the pathogenesis of systemic lupus ...

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across ...

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...